Table 2:

Potential long-term toxicities of new targeted therapies in the developing host.

Organ/system affected	Specific toxicity	Drugs
Growth and development	Short stature (due to IGF axis blockade)	TKI including BCR-ABL inhibitors
	Short stature (growth plate closure)	Antiangiogenics Sonic hedgehog inhibitors
Reproductive	Testicular and ovarian toxicity	ALK inhibitors
	Alterations of ovarian follicle development	Antiangiogenics
Nervous system	Neurotoxicity	Blinatumomab ALK inhibitors CAR-T cells Anti-GD2 monoclonal antibodies
	Visual disturbances	ALK inhibitors MEK inhibitors Anti-GD2 monoclonal antibodies
	Neurocognitive disfunction and psychiatric conditions	ALK inhibitors (lorlatinib)
Immune system	B-cell aplasia	Anti-CD19 CAR-T cells
	Autoimmune conditions	Anti-PD-1/PD-L1 agents
Endocrine system	Hypothyroidism	TKI
	Hyperglycemia and metabolic syndrome	ALK, PI3K, MEK inhibitors
Cardiovascular	Cardiac dysfunction	MEK inhibitors, TKI
	Hypertension	Antiangiogenics